We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Edwards Lifesciences (EW) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Edwards Lifesciences (EW - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? One simple way to answer this question is to take a look at the year-to-date performance of EW and the rest of the Medical group's stocks.
Edwards Lifesciences is one of 818 individual stocks in the Medical sector. Collectively, these companies sit at #2 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. EW is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for EW's full-year earnings has moved 1% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the latest available data, EW has gained about 24.01% so far this year. Meanwhile, stocks in the Medical group have gained about 2.71% on average. This means that Edwards Lifesciences is outperforming the sector as a whole this year.
Breaking things down more, EW is a member of the Medical - Instruments industry, which includes 92 individual companies and currently sits at #84 in the Zacks Industry Rank. This group has gained an average of 16% so far this year, so EW is performing better in this area.
EW will likely be looking to continue its solid performance, so investors interested Medical stocks should continue to pay close attention to the company.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Edwards Lifesciences (EW) Stock Outpacing Its Medical Peers This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Edwards Lifesciences (EW - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? One simple way to answer this question is to take a look at the year-to-date performance of EW and the rest of the Medical group's stocks.
Edwards Lifesciences is one of 818 individual stocks in the Medical sector. Collectively, these companies sit at #2 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. EW is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for EW's full-year earnings has moved 1% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the latest available data, EW has gained about 24.01% so far this year. Meanwhile, stocks in the Medical group have gained about 2.71% on average. This means that Edwards Lifesciences is outperforming the sector as a whole this year.
Breaking things down more, EW is a member of the Medical - Instruments industry, which includes 92 individual companies and currently sits at #84 in the Zacks Industry Rank. This group has gained an average of 16% so far this year, so EW is performing better in this area.
EW will likely be looking to continue its solid performance, so investors interested Medical stocks should continue to pay close attention to the company.